A Pilot Study Examining the Efficacy of a Support Algorithm for Commencing Patients with Type 2 Diabetes on a Basal / Prandial Insulin Regimen in the Primary Care Setting With Professional Continuous Glucose Monitoring as an Adjunct.

Sanofi Aventis0 个研究点目标入组 144 人开始时间: 2010年9月24日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•Type 2 diabetes patients who are insulin naive. Age>18 Years<80 Years. At least 2 oral hypoglycaemic agents (metformin, sulphonylurea, Thiazolidindiones) at maximal tolerated doses, or in the opinion of the responsible medical practitioner, insulin is deemed necessary if the patient is on less than 2 oral hypoglycaemic agents. The doses of the oral hypoglycaemic agents should be stable for at least 3 months prior to enrollment into the study. Haemoglobin A1c(HbA1c)>7.0%. Willing to monitor glucose levels at least twice daily. Willing to commence insulin and comply with follow-up.

•Type 1 diabetes.
•Evidence of satisfactory fasting glucose levels (mean <6.0mmol/L) with post-prandial hyperglycaemia (mean >10.0mmol/L).
•Previous or current treatment with insulin (excluding the short term (<2weeks) use of insulin in acute illness or during hospitalization).
•Non-English speaking.
•Significant cognitive impairment.
•Impaired vision or any other physical handicap precluding reliable glucose monitoring administration of insulin.
•Significant renal impairment: estimated glomerular filtration rate (egfr)< 20.
•Any recent (<3months) or ongoing life-threatening illness.
•Needle phobia.
•Pregnancy or planned pregnancy.
•Major psychiatric disorder.

发起方